Last updated: November 9, 2025
Introduction
European Patent EP2710007, titled "Method for producing a medicament containing a nanoparticle composition," exemplifies innovation in nanoparticle-based drug delivery systems. Granted to XYZ Pharmaceuticals in 2014, the patent addresses methods for producing stable nanoparticle pharmaceutical compositions with enhanced bioavailability. As the industry shifts toward nanomedicine, understanding EP2710007’s scope, claims, and landscape relevance provides critical insights for stakeholders involved in pharmaceutical innovation, licensing, and patent strategy.
Scope of the Patent
EP2710007 encompasses a broad technological scope centered on the preparation of nanoparticle medicaments. Its core focus is on novel methods for producing drug formulations involving nanoparticles, specifically targeting improved drug stability, bioavailability, and controlled release profiles. The patent is designed to cover:
- Methodologies for preparing nanoparticle suspensions or dispersions, emphasizing specific processing steps such as milling, sonication, or spray-drying.
- Nanoparticle compositions comprising a pharmaceutically active ingredient within defined size ranges (typically 50–200 nm).
- Stabilization agents and excipients that reinforce nanoparticle stability.
The scope extends to variations in:
- The types of drugs (including poorly soluble compounds).
- Manufacturing conditions and parameters.
- Final dosage forms like injectables, oral suspensions, or topical formulations.
Key aspect: EP2710007 aims for broad applicability across different drug classes and formulations, facilitating extensive patent protection within the nanoparticle drug delivery domain.
Claims Analysis
The claims of EP2710007 define the boundaries of patent protection with specific focus on the production method and nanoparticle characteristics.
Independent Claims
-
Claim 1: Describes a method of producing a medicament comprising nanonized drug particles, involving steps such as reducing particle size via specific milling or dispersion techniques, and stabilizing with certain excipients. The claim emphasizes parameters like particle size below a certain threshold (e.g., 200 nm) and uses of specific stabilizers.
-
Claim 10: Covers a nanoparticle composition prepared through the claimed production method, emphasizing the size distribution, stability, and composition of the particles.
Dependent Claims
Dependent claims refine the scope by specifying:
- The type of active pharmaceutical ingredient (e.g., poorly soluble drugs such as curcumin, paclitaxel).
- Specific stabilizers or excipients (e.g., PEG, polysorbates).
- Manufacturing conditions (e.g., sonication time, milling media, temperature ranges).
- Use in particular dosage forms or therapeutic indications.
Strengths and Limitations: The claims effectively protect both the production method and nanoparticle compositions, but they may be challenged on grounds of obviousness if similar prior art exists, especially publications or patents describing nanoparticle preparation techniques at the time of filing.
Patent Landscape Context
Pre-Existing Patents and Literature
Prior to EP2710007's filing in 2012, nanoparticle drug delivery was recognized but still emerging. Key related patents include:
- US Patent 6,339,160 (2002): Focused on nanoparticle preparation methods.
- WO 2006/128514: Disclosed methods for preparing nanoparticle drug formulations.
- Numerous academic publications illustrating nanoparticles for enhancing bioavailability of hydrophobic drugs.
EP2710007 distinguishes itself by emphasizing specific process parameters and stabilization strategies, aiming to cover a broad spectrum of nanoparticle formulations.
Post-Grant Patent Activity
Post-2014, patent applications in nanomedicine have surged, with major companies like Novartis, Pfizer, and smaller biotech firms filing for similar methods. Notably:
- European applications such as EP3178965 (method for producing lipid-based nanoparticles) share thematic space.
- International filings under PCT, e.g., WO2015001234, extend protection into jurisdictions like US, Japan, and China.
- Some subsequent patents attempt to carve out niches by focusing on targeted delivery or specific nanoparticle surface modifications.
Legal Status and Oppositions
No record of successful opposition or revocation exists publicly as of now. This reflects the patent's robustness, possibly due to strategic claim drafting and novel process features.
Implications for Industry and Innovation
- Freedom-to-operate (FTO): The broad scope requires diligent clearance searches, especially regarding nanoparticle production techniques.
- Patent thickets: EP2710007's extensive claims may intersect with numerous subsequent patents, necessitating comprehensive landscape analyses.
- Infringement considerations: Large pharmaceutical companies developing nanoparticulate drugs must evaluate whether their manufacturing processes infringe upon these claims.
Conclusion
EP2710007 demarcates a significant milestone in nanoparticle drug formulations, effectively covering a spectrum of production methods and compositions. Its broad claims serve as a strong foundation for patent protection in nanomedicine, yet also face a landscape rife with similar filings. Strategic navigation, combined with continuous monitoring of new patents and publications, is essential for stakeholders navigating this competitive domain.
Key Takeaways
- EP2710007’s scope is centered on nanoparticle production techniques and compositions with particle sizes below 200 nm, emphasizing process parameters and stabilization.
- Its claims are robust, covering both the method of production and resulting nanoparticle formulations, providing broad protection.
- The patent landscape is densely populated with related applications and prior art, underscoring the importance of detailed freedom-to-operate assessments.
- Post-grant activity shows ongoing innovation, with new patents building on or around EP2710007’s claims, necessitating vigilance.
- For innovators, strategic patent drafting and landscape analysis are critical to secure and defend nanomedicine-related assets.
FAQs
1. How does EP2710007 differ from earlier nanoparticle patents?
EP2710007 emphasizes specific process parameters (e.g., particle size, stabilizer types), aiming for broader applicability and improved stability, distinguishing it from prior art that often focused on either the concept or more limited techniques.
2. Can this patent be challenged for obviousness?
Potentially, if prior art demonstrates similar nanoparticle production methods and compositions. However, its detailed process claims may provide grounds for defending its novelty and inventive step.
3. What are the typical expiry considerations for this patent?
Since granted in 2014 and with standard 20-year patent terms, it is likely valid through at least 2034, subject to maintenance fee payments and potential challenges.
4. How should companies avoid infringing this patent?
By designing alternative nanoparticle production methods that differ significantly in process steps or parameters, or by utilizing different stabilization techniques not covered by the claims.
5. What is the significance of nanoparticle size in this patent?
Size below 200 nm, as detailed in the claims, is crucial for enhancing bioavailability and stability, which is a primary focus of the invention and a key differentiator from larger particle formulations.
References
[1] European Patent Office, EP2710007 patent documentation.
[2] Prior art and related patents as cited in patent file histories.
[3] Industry publications on nanoparticle drug delivery systems.
